Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

Luc Dirix, Helen Swaisland, Henk M. W. Verheul, Sylvie Rottey, Karin Leunen, Guy Jerusalem, Christian Rolfo, Dorte Nielsen, L. Rhoda Molife, Rebecca Kristeleit, Judith de Vos-Geelen, Morten Mau-Sorensen, Patricia Soetekouw, Carla van Herpen, Anitra Fielding, Karen So, Wendy Bannister, Ruth Plummer

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2286-2299
Number of pages14
JournalClinical Therapeutics
Volume38
Issue number10
DOIs
Publication statusPublished - Oct 2016

Keywords

  • CYP3A4
  • itraconazole
  • olaparib
  • pharmacokinetic
  • rifampin

Cite this

Dirix, L., Swaisland, H., Verheul, H. M. W., Rottey, S., Leunen, K., Jerusalem, G., Rolfo, C., Nielsen, D., Molife, L. R., Kristeleit, R., de Vos-Geelen, J., Mau-Sorensen, M., Soetekouw, P., van Herpen, C., Fielding, A., So, K., Bannister, W., & Plummer, R. (2016). Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. Clinical Therapeutics, 38(10), 2286-2299. https://doi.org/10.1016/j.clinthera.2016.08.010